Antioxidant Therapy for the Prevention of Type I Diabetes

Advances in Pharmacology

Volumn 38, Issue C, 1996, Pages 629-638

  Heller, Birgit ^a   Burkart, Volker ^a   Lampeter, Eberhard ^a   Kolb, Hubert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956731777     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)61002-9     Document Type: Article

References (49)

1. Appels B., Burkart V., Kantwerk-Funke G., Funda J., Kolb-Bachofen V., and Kolb H. Spontaneous cytotoxicity of macrophages against pancreatic islet cells. J. Immunol. 142 (1989) 3803-3808
2. Banasik M., Komura H., Shimoyama M., and Ueda K. Specific inhibitors of poly (ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 25 (1992) 1569-1575
3. Brenner H.-H., Burkart V., Rothe H., and Kolb H. Oxygen radical production is increased in macrophages from diabetes prone BB rats. Autoimmunity 15 (1993) 93-98
4. Burkart V., Koike T., Brenner H.-H., Imai Y., and Kolb H. Dihydrolipoic acid protects pancreatic islet cells from inflammatory attack. Agents Actions 38 (1993) 60-65
5. Burkart V., Koike T., Brenner H.-H., and Kolb H. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 35 (1992) 1028-1034
6. Chase H.P., Butler-Simon N., Garg S., Mcduffie M., Hoops S.L., and O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes. Diabetologia 33 (1990) 114-146
7. Elliot R.B., and Pilcher C.C. Prevention of diabetes in normal school children. Diab. Res. Clin. Pract. 14 Suppl. 1 (1991) 85
8. Faust A., Burkart V., Ulrich H., Weischer C.H., and Kolb H. Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice. Int. J. Immunopharmacol. 16 (1994) 61-66
9. Fehsel K., Jalowy A., Sun Q., Burkart V., Hartmann B., and Kolb H. Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes 42 (1993) 496-500
10. Grankvist K., Marklund S.L., and Talledal I.B. CuZn-superoxide dismutase, Mn-superoxid dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues of the mouse. Biochem. J. 199 (1981) 393-398
11. Guastamacchia E., Ciampolillo A., Lollino G., Caragiulo L., De Robeais O., Lattanzi V., and Giorgino R. Effetto della terapia con nicotinamide sull'induzione della durata della remissione clinica in diabetici di typo 1 all'esordio sottoposti a terapia insulinicaoaim-izzata mediante microinhsore. II Diabete (Suppl. 1) (1992) 210 Marzo
12. Haastert B., and Giani G. On the sequential design of the Deutsche Nikotinamid Interventionsstudie-DENIS. Diabete-Metab. 19 1 Pt 2 (1993) 100-104
13. Heller B., Bürkle A., Radons J., Fengler E., Jalowy A., Müller M., Burkart V., and Kolb H. Analysis of oxygen radical toxicity in pancreatic islets at the single cell level. Biochem. Biophys. Hoppe-Seyler 375 (1994) 597-602
14. Heller B., Wang Z.-Q., Wagner E., Radons J., Bürkle A., Fehsel K., Burkart V., and Kolb H. Inactivation of the poly(ADP-ribose)polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J. Biol. Chem. 270 (1995) 11176-11180
15. Hermitte L., Vialettes B., Atlef N., Payan M.J., Doll N., Scheinmann A., and Vague Ph. High dose nicotinamide fails to prevent diabetes in BB rats. Autoimmunity 5 (1989) 79-86
16. Ilkova H., Gorpe U., Kadioglu P., Ozyazar M., and Bagriacik N. Nicotinamide in type 1 diabetes mellitus of recent onset: A double blind, placebo controlled trial. Diabetologia 34 Suppl. 2 (1991) A179
17. Kallmann B., Burkart V., Kröncke K.-D., Kolb-Bachofen V., and Kolb H. Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Sci. 51 (1992) 671-678
18. Kolb H., and Kolb-Bachofen V. Nitric oxide: A pathogenetic factor in autoimmunity. Immunol. Today 13 (1992) 157-160
19. Kolb H., Schmidt M., and Kiesel U. Immunomodulary drugs in type 1 diabetes. In: Eisen-Barth G.S. (Ed). "Immunotherapy of Type 1 Diabetes and Selected Autoimmune Diseases" (1989), CRC Press, Boca Raton, FL 111-122
20. Kröncke K.-D., Brenner H.-H., Rodriguez M.-L., Etzkorn K., Noack E.A., Kolb H., and Kolb-Bachofen V. Pancreatic islet cells are highly susceptible toward the cytotoxic effects of chemically generated nitric oxide. Biochem. Biophys. Acta 1182 (1993) 221-229
21. Kröncke K.-D., Kolb-Bachofen V., Betschick B., Burkart V., and Kolb H. Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem. Biophys. Res. Commun. 175 (1991) 752-758
22. Lampeter E.F. Intervention with nicotinamide in pre-type 1 diabetes: The Deutsche Nikotinamid Interventionsstudie-DENIS. Diabete-Metab. 19 1 Pt 2 (1993) 105-109
23. Lazarow A. Protection against alloxan diabetes. Anat. Rec. 97 (1945) 353
24. Lazarow A., Liambies J., and Tausch A.J. Protection against diabetes with nicotinamide. J. Lab. Clin. Med. 38 (1950) 249-258
25. Lazarus S., and Shapiro S.H. Influence of nicotinamide and pyridine nucleotides on streptozotocin and alloxan induced pancreatic B cell cytotoxicity. Diabetes 22 (1973) 499-506
26. Lewis C.M., Canafax D.M., Sprafka J.M., and Barbosa J.J. Double-blind randomized trial of nicotinamide on early onset diabetes. Diabetes Care 15 (1992) 121-123
27. Loesberg C., Van Rooij H., and Smets L.A. Meta-iodobenzylguanidin (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Biochim. Biophys. Ada 1037 (1990) 92-99
28. Malaise W.J., Malaise-Lagae F., Sener A., and Pipeleers D.G. Determinants of the selective toxicity of alloxan to the pancreatic B-cell. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 927-930
29. Mandrup-Poulson T., Reimers J.I., Andersen H.U., Pociot F., Karlsen A.E., Bjerre U., and Nerup J. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabeted/Metab. Rev. 9 (1993) 295-309
30. Masiello P., Cubeddu T.L., Frosina G., and Bergamini E. Protective effect of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase, against streptozotocin-induced diabetes. Diabetologia 28 (1985) 683-686
31. Mendola G., Casamitjana R., and Gomis R. Effect of nicotinamide therapy upon β-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 32 (1989) 160-162
32. Mordes J.P., and Rossini A.A. Animal models of diabetes. Am. J. Med. 70 (1981) 353-360
33. Moss J., and Vaughan M. Activation of adenylate cyclase by choleragen. Annu. Rev. Biochem. 48 (1979) 581-600
34. Pozzilli P., Browne P.D., and Kolb H. Meta-analysis of nicotinamide treatment in patients with recent onset insulin dependent diabetes. Diabetes Care (1996) in press.
35. Pozzilli P., and on behalf of the IMDIAB Study group. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes. Diabetes Med. 17 (1994) 897-900
36. Pozzilli P., Visalli N., Ghirlanda G., Manna R., and Andreani D. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabetes Med. 6 (1989) 316-321
37. Pozzilli P., Vasalli N., Signore A., et al. Double blind trial of nicotinamide in recent onset insulin dependent diabetes mellitus. Diabetologia 38 (1995) 848-852
38. Rabinovitch A., Suarez W.L., Thomas P.D., Strynadka K., and Simpson I. Cytotoxic effects of cytokines on rat islets: Evidence for involvement of free radicals in lipid peroxidation. Diabetologia 35 (1992) 409-413
39. + depletion. Biochem. Biophys. Res. Commun. 199 (1994) 1270-1277
40. Rayfield E.J., and Ishimura K. Environmental factors and insulin-dependent diabetes mellitus. Diabetes/Metab. Rev. 3 (1987) 925-957
41. Rerup C.C. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol. Rev. 22 (1970) 485-520
42. Rossini A.A., Like A.A., Chick W.L., Appel M.C., and Cahill Jr. G.F. Studies of streptozotocin-induced insulitis and diabetes. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 2485-2489
43. Sarri Y., Mendola J., Ferrer J., and Gomis R. Preventive effects of nicotinamide administration on spontaneous diabetes of BB rats. Med. Sci. Res. 17 (1989) 987-988
44. Staman I., Dinccag N., Karsidag K., Ozer E., Altuntas Y., and Yilmaz M.T. The effect of nicotinamide in recent onset type 1 diabetes regarding the level of beta cell reserve. Klinik Gelisim 8 (1995) 3882-3886
45. Taboga C., Tonutti L., and Noacco C. Residual beta cell activity and insulin requirements in insulin-dependent diabetic patients treated from the beginning with high doses of nicotinamide: A two year follow-up. Recent Progr. Med. 85 (1994) 513-516
46. Wang Z.-Q., Auer B., Stingl L., Berghammer H., Haidacher D., Schweiger M., and Wagner E. Mice lacking ADPRT and poly(ADPribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 9 (1995) 509-520
47. Yamada K., Nonaka K., Hanafusa T., Miyazaki A., Toyoshima H., and Tarui S. Preventive and therapeutic aspects of large dose nicotinamide injections on diabetes associated with insulitis: An observation in non-obese diabetic (NOD) mice. Diabetes 31 (1982) 749-753
48. Yonemura Y., Takishima T., Miwa K., Miyazadi I., Yamamoto H., and Okamoto H. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Diabetes 33 (1984) 401-404
49. Zweier J.I., Kuppusamy P., and Lutty G.A. Measurement of endothelial cell free radical generation: Evidence for a central mechanism of free radical injury in postischaemic tissues. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4046-4050